CY1117709T1 - Αναλυτικη μεθοδος για μορια fab και fab' - Google Patents

Αναλυτικη μεθοδος για μορια fab και fab'

Info

Publication number
CY1117709T1
CY1117709T1 CY20161100528T CY161100528T CY1117709T1 CY 1117709 T1 CY1117709 T1 CY 1117709T1 CY 20161100528 T CY20161100528 T CY 20161100528T CY 161100528 T CY161100528 T CY 161100528T CY 1117709 T1 CY1117709 T1 CY 1117709T1
Authority
CY
Cyprus
Prior art keywords
fab
peg
analytical method
molecules
cleaved
Prior art date
Application number
CY20161100528T
Other languages
English (en)
Inventor
Bryan John Smith
Helen Marie Kirke
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of CY1117709T1 publication Critical patent/CY1117709T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)

Abstract

Μία μέθοδος για την καταμέτρηση των όξινων τμημάτων τα οποία δημιουργούνται από την αποδόμηση ενός συστατικού Fab ή Fab' ενός Fab-PEG ή ενός Fab'-PEG η οποία μέθοδος περιλαμβάνει τα ακόλουθα στάδια: α) τη διάσπαση της PEG και του συνδέτη από το Fab-PEG ή το Fab'-PEG με ένα ένζυμο, β) προαιρετικά το διαχωρισμό της PEG και του συνδέτη που δημιουργήθηκαν στο στάδιο α) από τα Fab ή Fab', για να παρασχεθούν τα Fab ή Fab' και γ) την ανάλυση με ποσοτικό προσδιορισμό των όξινων τμημάτων τα οποία σχετίζονται με το διασπασμένο Fab ή Fab' ή/και τη διασπασμένη PEG.
CY20161100528T 2010-07-29 2016-06-15 Αναλυτικη μεθοδος για μορια fab και fab' CY1117709T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1012784.3A GB201012784D0 (en) 2010-07-29 2010-07-29 Method
PCT/GB2011/001135 WO2012013933A1 (en) 2010-07-29 2011-07-28 Analytical method for fab and fab' molecules

Publications (1)

Publication Number Publication Date
CY1117709T1 true CY1117709T1 (el) 2017-05-17

Family

ID=42799323

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100528T CY1117709T1 (el) 2010-07-29 2016-06-15 Αναλυτικη μεθοδος για μορια fab και fab'

Country Status (22)

Country Link
US (2) US8722353B2 (el)
EP (1) EP2598888B1 (el)
JP (1) JP6122777B2 (el)
KR (1) KR20130143549A (el)
CN (1) CN103229058B (el)
AU (1) AU2011284551B2 (el)
BR (1) BR112013001160A2 (el)
CA (1) CA2805573A1 (el)
CY (1) CY1117709T1 (el)
DK (1) DK2598888T3 (el)
ES (1) ES2574906T3 (el)
GB (1) GB201012784D0 (el)
HK (1) HK1187674A1 (el)
HR (1) HRP20160554T1 (el)
HU (1) HUE027631T2 (el)
IL (1) IL224176A (el)
PL (1) PL2598888T3 (el)
PT (1) PT2598888E (el)
SG (1) SG187545A1 (el)
SI (1) SI2598888T1 (el)
SM (1) SMT201600173B (el)
WO (1) WO2012013933A1 (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201012784D0 (en) * 2010-07-29 2010-09-15 Ucb Pharma Sa Method
CN105548422B (zh) * 2015-12-23 2018-04-20 先健科技(深圳)有限公司 一种聚乙二醇含量的检测方法
CN108760962A (zh) * 2018-05-04 2018-11-06 上海药明生物技术有限公司 Fab或Fab’含量的测定方法及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
DE60336214D1 (de) * 2002-03-20 2011-04-14 Ucb Pharma Sa Methoden zur analyse von antikörperdisulfidisomere
CA2546054C (en) * 2003-12-10 2014-05-13 Medarex, Inc. Interferon alpha antibodies and their uses
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
GB201012784D0 (en) * 2010-07-29 2010-09-15 Ucb Pharma Sa Method

Also Published As

Publication number Publication date
IL224176A (en) 2015-10-29
WO2012013933A1 (en) 2012-02-02
AU2011284551A1 (en) 2013-01-31
HK1187674A1 (zh) 2014-04-11
ES2574906T3 (es) 2016-06-23
CA2805573A1 (en) 2012-02-02
CN103229058B (zh) 2015-07-29
AU2011284551B2 (en) 2016-04-07
US20140242625A1 (en) 2014-08-28
SG187545A1 (en) 2013-03-28
US9096887B2 (en) 2015-08-04
CN103229058A (zh) 2013-07-31
BR112013001160A2 (pt) 2021-03-30
PT2598888E (pt) 2016-06-23
SMT201600173B (it) 2016-08-31
JP6122777B2 (ja) 2017-04-26
GB201012784D0 (en) 2010-09-15
US20130183703A1 (en) 2013-07-18
US8722353B2 (en) 2014-05-13
HUE027631T2 (en) 2016-10-28
KR20130143549A (ko) 2013-12-31
EP2598888B1 (en) 2016-03-16
JP2013533490A (ja) 2013-08-22
HRP20160554T1 (hr) 2016-07-01
PL2598888T3 (pl) 2016-10-31
EP2598888A1 (en) 2013-06-05
DK2598888T3 (en) 2016-06-20
SI2598888T1 (sl) 2016-07-29

Similar Documents

Publication Publication Date Title
AU2018260845A1 (en) Evaluation and treatment of bradykinin-mediated disorders
DK2089343T3 (da) Click-kemi til fremstilling af reportermolekyler
BR112014025384A8 (pt) método e sistema para executar ensaio automatizado e métodos para executar teste reflexivo em vários exemplares
NO20080246L (no) Anti-IGF1R-antistofformuleringer
MX2016006454A (es) Dispositivo integrado con fuente de luz externa para sondear, detectar y analizar moleculas.
ATE514755T1 (de) Fluoreszenzfarbstoffe zur verwendung bei der glukoseerfassung
DE602006006200D1 (de) Antikörper gegen 25-hydroxyvitamin d
BR112015022766A2 (pt) sistemas de espectroscopia de fluorescência induzida por laser resolvida no tempo e método de uso do mesmo
ATE433124T1 (de) System und verfahren zum analysieren von radarinformationen
DE602006002809D1 (de) Verfahren zur erkennung eines ovarialkarzinoms
ATE512366T1 (de) Ms-verfahren zur evaluierung von glycanen
CL2008003784A1 (es) Anticuerpo humanizado anti proteina e2 del virus de la hepatitis c o un fragmento de union; acido nucleico que lo codifica; vector y celula huesped que comprenden dicho acido nucleico; metodo para producir el anticuerpo; composicion farmaceutica que comprende el anticuerpo
PH12015502849B1 (en) Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
EA201690213A1 (ru) Композиции и способ лечения связанных с комплементом состояний
DE602007013524D1 (de) Erkennung und vorhersage von frühgeburten
TW200702981A (en) Exception analysis methods and systems
BR112014026440A8 (pt) análises, métodos e aparelhos para avaliação de disrupção de rna.
CY1117709T1 (el) Αναλυτικη μεθοδος για μορια fab και fab'
WO2014144725A3 (en) Melatonin monoclonal antibody, detection, methods and uses thereof
ATE519116T1 (de) Verfahren zur normierung der konzentration von analyten in einer urinprobe
AU2011285694A8 (en) Detection of degradation products of canine NT-proBNP
DE602007011476D1 (de) Diagnostik-biomolekül(e)
WO2006053251A3 (en) Method of measuring amyloid-beta peptides
WO2011100752A3 (en) Methods and materials for assessing rna expression
WO2013076579A3 (en) Method for assessing risk of bone fracture